as of 12-31-2025 3:52pm EST
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $12.49 | Next Earning Date: | 11-04-2025 |
| Revenue: | $104,029,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 138.16% | Revenue Growth (next year): | 66.98% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Chief Scientific Officer
Avg Cost/Share
$9.78
Shares
23,726
Total Value
$231,931.14
Owned After
33,735
SEC Form 4
Director
Avg Cost/Share
$10.98
Shares
10,000
Total Value
$109,764.00
Owned After
23,983
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Burrows Francis | KURA | Chief Scientific Officer | Dec 18, 2025 | Sell | $9.78 | 23,726 | $231,931.14 | 33,735 | |
| Hasnain Faheem | KURA | Director | Dec 9, 2025 | Sell | $10.98 | 10,000 | $109,764.00 | 23,983 |
See how KURA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "KURA Kura Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.